Clinical trials: Early Alzheimers Disease
Alzheimer's Disease
Effects of Delivery Mode of Cognition Intervention in Early Alzheimer's Disease
The purpose of this study is to see if an intense two-week long cognitive training program helps the thinking ability of adults with very mild Alzheimer Disease.
- Trial name
- NCT00611312
- Testing
- Cognitive Training
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas
Alzheimer Disease
SV2A-PET/CT and PET/MRI Combined Clinical Criteria Score in the Diagnosis of Early Cognitive Alteration
Using SV2A-PET to character a cohort of patients with early cognitive impairment using the novel synaptic probe 18F-labeled difluoro-analog of UCB-J（also known as 18F-SDM-8）
- Trial name
- NCT06445582
- Testing
- [18F]SDM-8
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Alzheimer Disease
Detecting Early Alzheimer's Using MR
Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 10% of individuals aged ≥ 65. Most available treatments aim at controlling symptoms at an early stage rather than providing a cure.
- Trial name
- DREAMER (NCT05614310)
- Testing
- Magnetic Resonance Imaging (MRI), Blood Glucose Assessment, Positron Emission Tomography (PET)
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Alzheimer Disease, Healthy
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending…
- Trial name
- NCT06657768
- Testing
- LY4006895
- Where
- 13 sites in United States, Japan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Early Alzheimer's Disease
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional…
- Conditions
- Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
- Trial name
- NCT07512362
- Testing
- human Mesenchymal Stem Cells
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Bernard (Barry) Baumel
Depression, Pain
A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD
The purpose of the study is to examine the effect of Problem Adaptation Therapy for Pain (PATH-Pain) on cognitive functioning, depression and pain-related disability in 100 older adults with cognitive impairment, chronic pain…
- Conditions
- Depression, Pain, Cognitive Impairment
- Trial name
- PATH-Pain (NCT05081596)
- Testing
- PATH-Pain
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer's Disease
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of…
- Trial name
- MissionAD1 (NCT02956486)
- Testing
- Elenbecestat
- Where
- 258 sites in United States, Argentina and 16 more
- Volunteers
- 2,212 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia
Tau Imaging in Young Onset Dementia
The central goal of this study is to determine and compare the similarities and differences in regional brain uptake of [18F]T807 in patients with typical Alzheimer's Disease (AD), Posterior Cortical Atrophy (PCA), and Logopenic…
- Conditions
- Alzheimer's Disease, Early Onset, Logopenic Progressive Aphasia, Posterior Cortical Atrophy (PCA)
- Trial name
- NCT02289118
- Testing
- [18F]-T807 imaging tracer
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS
In this study the investigators aim at assessing and then enhancing neuroplasticity in the dorsolateral prefrontal cortex (DLPFC) and working memory - a key function of DLPFC - in patients with mild Alzheimer's disease (AD).
- Trial name
- rTMS-AD (NCT02537496)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Alzheimer Disease, Early Onset Alzheimer Disease
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild…
- Trial name
- NCT03634007
- Testing
- LX1001
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lexeo Therapeutics
Alzheimer Disease, Mild Cognitive Impairment
TPSAlz - Transcranial Pulse Stimulation in Alzheimer's Disease
The goal of this study is to evaluate the effects of transcranial pulse stimulation (TPS) in modulating cognitive functions as well as structural and functional connectivity in individuals with mild cognitive impairment and early…
- Trial name
- TPSAlz (NCT07883148)
- Testing
- Transcranial pulse stimulation (TPS)
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- IRCCS San Raffaele Roma
Alzheimer's Disease
Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease
By doing this study, researchers will examine the safety and tolerability of R-pramipexole in participants with Alzheimer's disease.
- Trial name
- NCT01388478
- Testing
- R-pramipexole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Alzheimer Disease, Biomarker in Early Diagnosis
miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction
Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities.
- Trial name
- NCT07353502
- Testing
- Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Mild Cognitive Impairment, Alzheimer's Disease
Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology
One purpose of this study is to construct the diagnosis system for early Alzheimer's disease(AD), which is also called amnestic mild cognitive impairment (aMCI), and then further construct the predictable classifier from aMCI to…
- Trial name
- NCT02353845
- Where
- China
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- XuanwuH 2
Alzheimer Disease, Mild Cognitive Impairment
Orientation in AD Patients: PET-MR Study
Despite the high prevalence of Alzheimer's disease (AD), its underlying mechanisms remain poorly understood. An emerging body of evidence supports disorientation as an early marker for AD-related neurodegeneration.
- Trial name
- NCT03030365
- Testing
- Siemens "Biograph mMR" PET-MR (3T)
- Volunteers
- 30 people
- Sponsor
- Assuta Medical Center
Alzheimer Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 in participants in the early Alzheimer's disease (AD [progressive brain disease that slowly destroys memory and thinking skills, and…
- Trial name
- NCT02406027
- Testing
- JNJ-54861911, 10 mg, JNJ-54861911, 25 mg, JNJ-54861911, 5 mg
- Where
- 17 sites in Belgium, France and 4 more
- Volunteers
- 90 people
- Sponsor
- Janssen Research & Development, LLC
Alzheimer's Disease(AD)
12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease
This is a 12-month, single-arm, real-world study designed to evaluate the efficacy and safety of lecanemab (10 mg/kg administered every two weeks) in patients with early Alzheimer's disease, including mild cognitive impairment…
- Trial name
- NCT07034222
- Testing
- Administer Leqemi 10 mg/kg, every two weeks.
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Ruijin Hospital
Alzheimer Disease
TMS Pilot in Early AD II
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion.
- Trial name
- NCT06817902
- Testing
- Intermittent theta burst stimulation active coil
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- HealthPartners Institute
Alzheimer Disease
Pregnenolone Sulfate an Early Marker of the Memory Loss in Alzheimer's Disease
The steroid pregnenolone sulfate (PREGS) may be one of the factors responsible for the memory decline related to normal aging or associated with Alzheimer's disease (AD).
- Trial name
- STERMEM (NCT00912886)
- Where
- 6 sites in France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease, Early Onset
Eardream Data Collection in Colombia Supported by ADDF
Data collection based on this study will allow us to collect neurophysiological and cognitive data collected from in-ear EEG recordings of the Autosomal dominant alzheimer's disease population in Colombia
- Trial name
- NCT05570370
- Testing
- This is an observational study
- Where
- Colombia
- Volunteers
- 120 people
- Sponsor
- Swiss Federal Institute of Technology